TLDR
- Eli Lilly has entered into its seventh partnership with Innovent Biologics, aiming to jointly develop treatments for cancer and immune diseases.
- Under the agreement, Lilly will secure exclusive worldwide development and commercialization rights for new drugs outside of Greater China.
- The deal includes an initial payment of $350 million to Innovent, with the potential for up to $8.5 billion in milestone payments.
- This collaboration signifies a shift towards joint drug development, moving beyond simply licensing existing treatments from Chinese partners.
- The partnership underscores the ongoing cooperation between U.S. and Chinese life sciences companies, even amidst geopolitical tensions.
Eli Lilly announced on Sunday an significant expansion of its partnership with Chinese drugmaker Innovent Biologics. This marks the seventh collaboration between the two companies, with a focus on developing treatments for cancer and immune system disorders.
Eli Lilly is paying $350 million upfront to collaborate with Chinese biotech Innovent in developing new treatments for cancer and immune disorders, a further vote of confidence for the innovation capabilities of the country’s drugmakers
— Bloomberg (@business)
The major pharmaceutical company will obtain exclusive global rights for the development and commercialization of new medicines outside of Greater China. Innovent will be responsible for the early stages of development, including Phase 2 clinical trials conducted within China.
As part of the agreement, Lilly will provide Innovent with an upfront payment of $350 million. The Chinese company is also eligible to receive milestone payments that could total approximately $8.5 billion.
Additionally, Innovent will be entitled to receive tiered royalties on sales of any products that Lilly brings to market. This financial arrangement links payments to the progress of development and the commercial success of the drugs.
Innovent’s shares experienced a 7% increase in Hong Kong trading on Monday following the announcement. The stock had initially seen a surge of up to 8.6% before closing with a 7% gain.
New Approach to Drug Development
This current partnership represents a departure from previous agreements between the two companies, which primarily involved acquiring rights to Innovent’s existing treatments.
The new collaboration centers on the joint development of drugs from their initial stages. Innovent has characterized this arrangement as the creation of an “end-to-end innovation ecosystem.”
“The deal is a positive surprise to the market,” stated Cui Cui, Jefferies’ head of Asia healthcare research. He added that the framework demonstrates a long-term commitment to partnership between the firms.
This structure will enable Innovent to advance multiple pipeline assets into mid-stage clinical testing. Lilly will then assume responsibility for later-stage development and global commercialization efforts.
The division of responsibilities is designed to accelerate global development timelines. Innovent contributes its antibody discovery platforms and local clinical trial expertise, while Lilly brings its capabilities in later-stage development.
Accessing China’s Growing Biotech Pipeline
This collaboration is part of a broader trend where Western pharmaceutical companies are partnering with Chinese biopharmaceutical firms. These alliances provide access to China’s rapidly expanding pipeline of innovative therapies.
China’s cost-effective research and development environment is a significant draw for international partners. Furthermore, the country’s large patient populations facilitate quicker enrollment in clinical trials.
Jialin Zhang, a Nomura China healthcare analyst, commented that the partnership enhances the clinical and commercial prospects for new drugs. She also noted that Innovent’s R&D platform receives validation through this ongoing cooperation with Lilly.
The continued collaboration with Chinese companies suggests that a significant decoupling of life sciences between the U.S. and China is unlikely in the near future, as highlighted by Zhang in her analysis.
The companies have not disclosed the exact number of drug candidates included in the deal. Both firms have confirmed that the focus will be on oncology and immunology programs.
No specific timelines for achieving clinical milestones have been provided. Both companies are already actively engaged in research and development within these therapeutic areas.
The structure of the agreement allows Lilly to tap into innovation while managing its early-stage development expenses. Innovent will conduct proof-of-concept studies before Lilly exercises its worldwide rights.
The Hang Seng Biotech Index has seen a year-to-date increase of over 9%, outperforming the broader Hang Seng Index and reflecting investor optimism in the sector’s growth.
Innovent will retain commercialization rights within Greater China for any products developed through this partnership, thereby preserving its ability to generate revenue in its domestic market.
